

## Curriculum Vitae



**Ronald A. Marchesani**  
**rmarchesani@bcg-usa.com**  
Senior Consultant  
Biologics Consulting Group, Inc.  
San Mateo, CA  
C 650-863-2578  
F 650-525-9403

### **EDUCATION**

**BSc** *Chemistry and Biology*, University of Miami, Coral Gables, Florida (1975)

### **EXPERIENCE**

**Biologics Consulting Group, Inc.**, *Senior Consultant*  
San Mateo, CA (Feb. 2007 - present)

**Genentech**, *Senior Director, Corporate GMP Compliance*  
South San Francisco, CA (July 2005 – Jan. 2007)

**ID Biomedical Corporation**, *Vice President, Global Quality Control*  
Laval, Quebec, Canada (Sept 2004 - July 2005)

**Shire Biologics**, *Vice President, Quality, Project Manager, Biological Warfare Vaccine System Support*  
Laval, Quebec, Canada (Jan 2003 – Sept 2004)

**Acambis**, *Senior Director of Quality Systems*  
Cambridge, MA (Aug 1998 - Jan 2003)

**Acambis** (Formerly known as OraVax ) *Senior Director of Regulatory & Quality Affairs* (Apr 1999 - Jan 2002)  
Cambridge, MA

**Acambis** (Formerly known as OraVax ) *Senior Director of Quality Assurance & Validation*  
(Aug 1998 - Apr 1999)  
Cambridge, MA

**Creative Biomolecules**, *Director of Quality Control*  
Hopkinton, MA (May 1997 - July 1998)

**ImmuLogic Pharmaceutical Corporation**, *Director of Quality Assurance & Quality Control*  
Waltham, MA (Apr 1992 - May 1997)

**Genzyme Corporation**, *Quality Control Manager*  
Cambridge, MA (1988 – 1992)

#### **CONTINUING EDUCATION**

2003 Tulane University, Freeman School of Business, MBA Certificate Program  
2002 Kellogg School of Management, Evanston, IL, Executive Development  
Program for Senior Regulatory Professionals  
Dec 1989 Northeastern University, Boston, Massachusetts, Postgraduate course: Electro  
analytical Chemistry  
July 1981 University of Tennessee, Memphis, Tennessee, Postgraduate course:  
Preparation of Parenteral Medications  
1976 - 1978 Department of Biochemistry, School of Medicine, University of Miami, Coral  
Gables, Florida, Biochemistry & Molecular Biology courses

#### **PROFESSIONAL SOCIETIES**

- PDA, New England Chapter Activity Board Member (1992-2003)
- Member PDA
- Member AQC
- Member ISPE
- Member DIA

#### **LEADERSHIP**

- PDA Canadian Chapter, Secretary (2004-2006)
- National Institutes of Health/ National Institute of Allergy & Infectious Diseases, Special  
Emphasis Panel Meeting “DMID Clinical Trials Management”, Chairperson (May 2003)
- National Institutes of Health/ National Institute of Allergy & Infectious Diseases, Special  
Emphasis Panel Meeting (2001)

#### **SELECTED ORAL PRESENTATIONS**

April 2006 Annual PDA Meeting, Speaker –Vaccines Focus Group., Challenges and  
Insight into Preparation for an FDA Inspection” (Anaheim, CA)  
September 2005 Joint FDA/PDA Conference, Speaker –Vaccines Focus Group, Round  
Table Discussion (Washington D.C.)  
September 2004 Joint FDA/PDA Conference (Washington D.C.)  
May 2004 RAPS Canadian Conference (Toronto, ON, Canada)  
April 2004 World Vaccine Congress, Speaker “Working with governments to  
accelerate vaccine candidates’ time to market (Montreal, Canada)



- April 2004 BioDefense Conference, (Washington D.C.)
- October 2003 BioDefense Conference, (Washington D.C.)
- October 2003 Workshop on Counter Terrorism Products Regulated by the Center for Biologics Evaluation and Research: Effective Strategies to Assist in Product Development (Bethesda, MD)
- October 2003 Canadian Conference on Counter-Terrorism and Public Health (Toronto, ON, Canada)
- July 2003 RAPS Due Diligence Conference (Rockville, MD)

#### **BIBLIOGRAPHY**

1. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections, et al, Vaccines, Volume 20, Issues 7-8, January 2002, Pages 1004-1018
2. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in a Phase III multicenter, double-blind clinical trial, et al, American Journal of Tropical Medicine and Hygiene, Vol. 66, No. 5, 533-541